Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. - Wikidata - awgldk - TriplyDB

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

http://www.wikidata.org/entity/Q37553108

about

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View Piwil 2 gene transfection changes the autophagy status in a rat model of diabetic nephropathy.Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.Potassium: friend or foe?Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy Serum potassium in dual renin-angiotensin-aldosterone system blockade.Does cardiovascular protection translate into renal protection?Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?

P2860

Q26795398-2592D5AA-51E4-49AC-9831-9116ED2D4B0F Q35682234-3A4430EB-5B76-4BD1-BCD9-347910861F1E Q36261516-2D12D56F-E7D3-48BC-AFF0-645D0E9D2DF7 Q36329456-694261E3-7D7B-4262-82B8-672101CCCF66 Q38777543-70D6DE10-D4B7-4608-8B5B-0D2DD4B54621 Q38838019-9E57FA67-A80C-480C-8834-A64063E3F994 Q40965113-75B51A2D-ADF9-4499-A246-22C3295488AC Q42624224-38B6D85B-BFCB-465E-8DE8-0A5664397A18 Q42670795-CD20B0F9-75F9-4A96-A495-1956B40CD9F6 Q53563573-4261A399-4225-403F-8AD2-5C312AC85304

P2860

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

http://www.wikidata.org/entity/Q37553108

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@en

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@nl

type

label

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@en

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@nl

prefLabel

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@en

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@nl

P1433

Q37553108-98D82481-7A15-4C17-992D-9F0084C92F04

P1476

Q37553108-FDA7CC89-6D30-4422-84AB-42267243C372

P2093

Q37553108-2B1523E0-95C4-4D54-B1F4-7A69944F693E

Q37553108-7D0B42FF-D31D-4D29-8496-0198622E7C1E

Q37553108-83D254E2-D93F-41CB-9E50-FA439D12F6F8

Q37553108-AC86EC8C-05E9-4EBA-844B-783254C90C48

Q37553108-DB5926EC-1754-4146-9357-3208571F51B4

P2860

Q37553108-0048B2DD-FA67-41C9-BC84-67F160770A87

Q37553108-049BEA21-B403-4CA9-BFCF-2570595774AA

Q37553108-078C5C4C-1770-4314-8DF7-05C1A96F4AD1

Q37553108-1181EBBF-DD4D-4730-B106-51A7D3C10D14

Q37553108-1300E093-D9D2-46F5-8EEE-0C2BABA18B8D

Q37553108-1C566283-2724-4DE2-A878-C707F88D3342

Q37553108-46AF8C98-CDFD-4C8E-82D4-BE14713D0FB3

Q37553108-4CFA4374-9373-4B6B-B724-07B177A61515

Q37553108-4DE1F927-68D5-479C-BA72-E23841DC086A

Q37553108-5127037A-E823-4C7F-85AB-7AF0A92415A6

P304

Q37553108-11211A86-31E3-4AE4-8132-7F274A7B60E4

P31

Q37553108-7D43247B-A8A7-4EDD-97E4-313B239746CD

P356

Q37553108-E69F085A-18C6-4076-AE38-E6F5696F001B

P433

Q37553108-F8449E7B-5424-4E38-85C7-473EFC28DCD5

P478

Q37553108-43002487-D751-40EA-9D6F-79BCC5539145

P577

Q37553108-31F70231-35A3-4CBA-B0FF-0C5C0B327A17

P698

Q37553108-6986EFA0-31E4-42E5-A70F-0E7175F0980E

P932

Q37553108-97092FA4-8ED3-409F-9DCC-F4D5DD8FE48B

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

@en

P2093

Beverley Adams-Huet

http://www.w3.org/2001/XMLSchema#string

Christopher Molina

http://www.w3.org/2001/XMLSchema#string

Mark Nguyen

http://www.w3.org/2001/XMLSchema#string

Peter N Van Buren

http://www.w3.org/2001/XMLSchema#string

Robert D Toto

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

An extrarenal mechanism of potassium adaptation

P304

295-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.07460713

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24408116

http://www.w3.org/2001/XMLSchema#string

P932

3913245

http://www.w3.org/2001/XMLSchema#string